Medications 360 Study

The RAPID Alliance Medications 360 study is bringing together senior leaders, experts and scholars from across the US, the 50 states and DC, to co-create a strategic roadmap and actionable next steps for optimizing use of medications, vaccines and related therapies for US populations.

This study builds on a 2020 research study, conducted during the COVID-19 pandemic, that identified strategic opportunities to improve health and wellbeing for the US population while reducing spending on likely-avoidable hospitalizations, emergency department and doctor visits by as much as $528 billion by optimizing medications and vaccine use.

The study design calls for balanced representation from across the US medication use ecosystem, including but not limited to, 11 stakeholder groups (e.g., patient advocates, physicians, nurses and clinicians, pharmacists and pharmacies, pharmaceutical manufacturers, health systems, aging care providers, health plans and plan sponsors, digital health and interoperability organizations, standards and measures organizations, government and policy leaders and university-based researchers).

Study topics include health equity and empowerment, value-driven payment and practice models, interoperability, digital technologies, measurement and attribution standards, influenza and COVID-19 vaccine uptake, and national research priorities.

Project partners include the Frazier Polypharmacy Program, the UofL Center for Health Organization Transformation (CHOT), and the RAPID Alliance Research Consortium. UofL’s Judah Thornewill, PhD, Demetra Antimisiaris, PharmD, Robert Esterhay, MD, William Yasnoff, MD, PhD and Tom Walton, MDiv are the study’s co- investigators.

Learn more, or apply to join the study, at

Stay connected TwitterFacebook LinkedIn YouTubeInstagram